|
Volumn 3, Issue 3, 2003, Pages 257-259
|
Iressa®: First angiogenesis inhibitor approved for the treatment of advanced NSCLC
[No Author Info available]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BISPHOSPHONIC ACID DERIVATIVE;
CANCER VACCINE;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR;
EPIDERMAL GROWTH FACTOR DERIVATIVE;
ESTROGEN RECEPTOR;
GEFITINIB;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
PLACEBO;
PROTEIN KINASE C;
RECOMBINANT ERYTHROPOIETIN;
TAMOXIFEN;
TELOMERASE INHIBITOR;
ZOLEDRONIC ACID;
ACNE;
ADVANCED CANCER;
ANEMIA;
BONE METASTASIS;
BREAST CANCER;
CANCER IMMUNOTHERAPY;
CLINICAL TRIAL;
DEHYDRATION;
DIARRHEA;
DOSE RESPONSE;
DRUG APPROVAL;
DRUG INDUCED DISEASE;
DRUG TARGETING;
DRUG TOLERABILITY;
DRY SKIN;
HUMAN;
INTERSTITIAL PNEUMONIA;
LUNG ALVEOLITIS;
LUNG NON SMALL CELL CANCER;
NAUSEA;
NONHUMAN;
NOTE;
PATHOLOGIC FRACTURE;
PRACTICE GUIDELINE;
PROSTATE CANCER;
RASH;
TABLET FORMULATION;
TREATMENT FAILURE;
VOMITING;
|
EID: 0038207110
PISSN: 14737140
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
Times cited : (1)
|
References (0)
|